GuiZhou SanLi Pharmaceutical Co.,Ltd
SSE:603439.SS
12.16 (CNY) • At close June 6, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 2,144.386 | 1,634.978 | 1,201.316 | 938.966 | 630.225 | 883.783 | 722.346 | 638.331 | 514.609 | 359.042 | 266.878 | 159.326 |
| Kosten van de omzet
| 649.987 | 436.311 | 339.505 | 277.007 | 208.979 | 298.756 | 249.774 | 214.017 | 179.915 | 135.647 | 101.493 | 60.72 |
| Brutowinst
| 1,494.399 | 1,198.667 | 861.812 | 661.959 | 421.246 | 585.027 | 472.572 | 424.314 | 334.694 | 223.395 | 165.385 | 98.606 |
| Brutowinstmarge
| 0.697 | 0.733 | 0.717 | 0.705 | 0.668 | 0.662 | 0.654 | 0.665 | 0.65 | 0.622 | 0.62 | 0.619 |
| Onderzoek- en ontwikkelingskosten
| 46.504 | 30.611 | 17.863 | 7.681 | 5.631 | 3.511 | 6.863 | 5.4 | 5.622 | 0.689 | 0.133 | 0.037 |
| Algemene en administratieve kosten
| 35.855 | 27.987 | 20.708 | 16.134 | 9.954 | 6.576 | 8.503 | -1.653 | 3.739 | 4.268 | 4.27 | 2.972 |
| Verkoop- en marketingkosten
| 761.62 | 794.46 | 562.622 | 450.837 | 276.751 | 393.942 | 337.182 | 302.615 | 238.442 | 156.962 | 120.357 | 69.826 |
| Verkoop-, algemene en administratieve kosten
| 797.476 | 820.672 | 583.33 | 466.972 | 286.705 | 400.518 | 345.685 | 300.962 | 242.181 | 161.23 | 124.626 | 72.799 |
| Overige kosten
| 324.171 | 11.555 | 36.622 | 24.285 | 20.915 | 26.221 | 30.363 | 15.642 | 20.66 | 10.431 | 1.744 | 7.008 |
| Bedrijfskosten
| 1,168.15 | 862.838 | 637.815 | 498.938 | 313.251 | 430.249 | 373.1 | 336.451 | 264.729 | 172.473 | 132.778 | 78.191 |
| Bedrijfsresultaat
| 326.249 | 335.829 | 225.549 | 179.192 | 112.27 | 154.596 | 99.777 | 87.53 | 66.613 | 50.834 | 32.246 | 16.808 |
| Bedrijfsresultaat ratio
| 0.152 | 0.205 | 0.188 | 0.191 | 0.178 | 0.175 | 0.138 | 0.137 | 0.129 | 0.142 | 0.121 | 0.105 |
| Totaal overige inkomsten en kosten netto
| -1.223 | -1.806 | -2.99 | -2.542 | -2.373 | 1.198 | 30.363 | 15.918 | 20.66 | 10.431 | 1.739 | 5.859 |
| Inkomen voor belasting
| 325.025 | 334.022 | 222.559 | 176.65 | 109.897 | 155.794 | 130.14 | 103.448 | 87.273 | 61.265 | 33.985 | 22.667 |
| Inkomen voor belasting ratio
| 0.152 | 0.204 | 0.185 | 0.188 | 0.174 | 0.176 | 0.18 | 0.162 | 0.17 | 0.171 | 0.127 | 0.142 |
| Belastingkosten
| 45.188 | 39.153 | 30.621 | 28.049 | 15.946 | 22.725 | 19.659 | 15.82 | 12.393 | 8.654 | 4.99 | 3.294 |
| Nettowinst
| 274.028 | 292.703 | 201.284 | 152.283 | 93.953 | 133.082 | 110.483 | 87.628 | 74.88 | 52.61 | 28.994 | 19.373 |
| Nettowinstmarge
| 0.128 | 0.179 | 0.168 | 0.162 | 0.149 | 0.151 | 0.153 | 0.137 | 0.146 | 0.147 | 0.109 | 0.122 |
| WPA (Winst Per Aandeel)
| 0.67 | 0.71 | 0.49 | 0.37 | 0.23 | 0.33 | 0.3 | 0.24 | 0.22 | 0.17 | 0.094 | 0.063 |
| Verwaterde WPA
| 0.67 | 0.71 | 0.49 | 0.37 | 0.23 | 0.33 | 0.3 | 0.24 | 0.22 | 0.17 | 0.094 | 0.063 |
| EBITDA
| 415.411 | 369.183 | 243.993 | 191.582 | 112.979 | 159.722 | 138.021 | 95.199 | 91.101 | 63.593 | 34.745 | 19.843 |
| EBITDA ratio
| 0.194 | 0.226 | 0.203 | 0.204 | 0.179 | 0.181 | 0.191 | 0.149 | 0.177 | 0.177 | 0.13 | 0.125 |